Rupatadine for the treatment of allergic rhinitis and urticaria

Expert Review of Clinical Immunology

Volumn 7, Issue 1, 2011, Pages 15-20

  Metz, Martin ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

allergic rhinitis; antihistamine; PAF antagonist; rupatadine; urticaria

Indexed keywords

1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; ALLERGEN; ANTIHISTAMINIC AGENT; APAFANT; ASTEMIZOLE; AZITHROMYCIN; CETIRIZINE; CORTICOSTEROID; EBASTINE; ERYTHROMYCIN; GINKGOLIDE B; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; PLACEBO; RUPATADINE; TERFENADINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOTAXIS; CHRONIC URTICARIA; COLD URTICARIA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FOOD; HAY FEVER; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MENTAL DETERIORATION; MULTICENTER STUDY (TOPIC); NASAL PRURITUS; NONHUMAN; NOSE CONGESTION; PERENNIAL RHINITIS; PHARMACODYNAMICS; PRACTICE GUIDELINE; PSYCHOMOTOR DISORDER; QT PROLONGATION; QUALITY OF LIFE; RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINORRHEA; SINGLE DRUG DOSE; SKIN MANIFESTATION; SNEEZING; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT INDICATION; URTICARIA;

ANTI-ALLERGIC AGENTS; CHRONIC DISEASE; CYPROHEPTADINE; HISTAMINE H1 ANTAGONISTS; HUMANS; PLATELET ACTIVATING FACTOR; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; URTICARIA;

EID: 78650524720     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.85     Document Type: Article

References (48)

1. Bousquet J, Burney PG, Zuberbier T et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma epidemic. Allergy 64(7), 969-977 (2009).
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 63(Suppl. 86), 8-160 (2008). (Pubitemid 351357811)
3. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108(Suppl. 5), S147-S334 (2001).
4. Greaves MW. Chronic idiopathic urticaria. Curr. Opin. Allergy Clin. Immunol. 3(5), 363-368 (2003).
5. Magerl M, Pisarevskaja D, Scheufele R, Zuberbier T, Maurer M. Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy 65(1), 78-83 (2010).
6. Metz M, Gimenez-Arnau A, Borzova E, Grattan CE, Magerl M, Maurer M. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. J. Allergy Clin. Immunol. 123(3), 705-706 (2009).
7. Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br. J. Dermatol. 154(2), 294-298 (2006).
8. Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergologica 2005. J. Investig. Allergol. Clin. Immunol. 19(Suppl. 2), 21-26 (2009).
9. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J. Investig. Allergol. Clin. Immunol. 14(3), 214-220 (2004).
10. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin. Exp. Dermatol. 35(8), 869-873 (2010).
11. Mlynek A, Magerl M, Hanna M et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 64(6), 927-936 (2009).
12. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic urticaria. A GA2LEN Task Force Report. Allergy (In Press) (2010).
13. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 64(10), 1427-1443 (2009).
14. Annesi-Maesano I, Beyer A, Marmouz F, Mathelier-Fusade P, Vervloet D, Bauchau V. Do patients with skin allergies have higher levels of anxiety than patients with allergic respiratory diseases? Results of a large-scale cross-sectional study in a French population. Br. J. Dermatol. 154(6), 1128-1136 (2006).
15. Bousquet J, Reid J, van Weel C et al. Allergic rhinitis management pocket reference 2008. Allergy 63(8), 990-996 (2008).
16. Derebery J, Meltzer E, Nathan RA et al. Rhinitis symptoms and comorbidities in the United States: burden of rhinitis in America survey. Otolaryngol. Head Neck Surg. 139(2), 198-205 (2008).
17. Vasiadi M, Kalogeromitros D, Kempuraj D et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int. Arch. Allergy Immunol. 151(1), 38-45 (2010).
18. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 67(3), 457-474 (2007).
19. Mullol J, Bousquet J, Bachert C et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 63(Suppl. 87), 5-28 (2008).
20. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin. Pharmacother. 7(14), 1989-2001 (2006).
21. Stuebner P, Horak F, Zieglmayer R et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann. Allergy Asthma Immunol. 96(1), 37-44 (2006).
22. Queralt M, Brazis P, Merlos M, de Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-a release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm. Res. 49(7), 355-360 (2000).
23. Solans A, Izquierdo I, Donado E et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Clin. Ther. 30(9), 1639-1650 (2008).
24. Solans A, Carbo ML, Pena J, Nadal T, Izquierdo I, Merlos M. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin. Ther. 29(5), 900-908 (2007).
25. Fantin S, Maspero J, Bisbal C et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 63(7), 924-931 (2008).
26. Martinez-Cocera C, De Molina M, Marti-Guadano E et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J. Investig. Allergol. Clin. Immunol. 15(1), 22-29 (2005).
27. Saint-Martin F, Dumur JP, Perez I, Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 14(1), 34-40 (2004)
28. Guadano EM, Serra-Batlles J, Meseguer J et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 59(7), 766-771 (2004).
29. Gimenez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J. Eur. Acad. Dermatol. Venereol. 23(9), 1088-1091 (2009).
30. Krause K, Zuberbier T, Maurer M. Modern approaches to the diagnosis and treatment of cold contact urticaria. Curr. Allergy Asthma Rep. 10(4), 243-249 (2010).
31. Grandel KE, Farr RS, Wanderer AA, Eisenstadt TC, Wasserman SI. Association of platelet-activating factor with primary acquired cold urticaria. N. Engl. J. Med. 313(7), 405-409 (1985).
32. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, Maurer M. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann. Allergy Asthma Immunol. 104(1), 86-92 (2010).
33. Dubertret L, Zalupca L, Cristodoulo T et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur. J. Dermatol. 17(3), 223-228 (2007).
34. Gimenez-Arnau A, Pujol RM, Ianosi S et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 62(5), 539-546 (2007).
35. Valero A, de la Torre F, Castillo JA et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 32(1), 33-42 (2009).
36. Donado E, Izquierdo I, Perez I et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a thorough QT/QTc study performed according to ICH guidelines. Br. J. Clin. Pharmacol. 69(4), 401-410 (2010).
37. Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today 39(6), 451-468 (2003).
38. Davila I, Sastre J, Bartra J et al. Effect of H1 antihistamines upon the cardiovascular system. J. Investig. Allergol. Clin. Immunol. 16(Suppl. 1), 13-23 (2006). (Pubitemid 46057826)
39. Hove-Madsen L, Llach A, Molina CE et al. The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur. J. Clin. Pharmacol. 553(1-3), 215-221 (2006). (Pubitemid 44779593)
40. Church MK, Maurer M, Simons FE et al. Risk of first-generation H(1)- antihistamines: a GA2LEN position paper. Allergy 65(4), 459-466 (2010).
41. Merlos M, Giral M, Balsa D et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther. 280(1), 114-121 (1997).
42. Barbanoj MJ, Garcia-Gea C, Morte A, Izquierdo I, Perez I, Jane F. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet- activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 50(4), 311-321 (2004).
43. Vuurman E, Theunissen E, van Oers A, van Leeuwen C, Jolles J. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum. Psychopharmacol. 22(5), 289-297 (2007).
44. Vadas P, Gold M, Perelman B et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N. Engl. J. Med. 358(1), 28-35 (2008).
45. Kajiwara N, Sasaki T, Bradding P et al. Activation of human mast cells through the platelet-activating factor receptor. J. Allergy Clin. Immunol. 125(5), 1137.e6-1145.e6 (2010).
46. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat. Inflamm. Allergy Drug Discov. 2(1), 72-76 (2008).
47. Montrucchio G, Alloatti G, Mariano F, Tetta C, Emanuelli G, Camussi G. Cardiovascular alterations in the rabbit infused with platelet activating factor (PAF): effect of kadsurenone, a PAF-receptor antagonist. Int. J. Tissue React. 8(6), 497-504 (1986).
48. Dyer KD, Percopo CM, Xie Z et al. Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor. J. Immunol. 184(11), 6327-6334 (2010).